Screening for prostate cancer using prostate-specific antigen (PSA) is widely used in the general population, contributing to a threefold increase in the incidence of diagnosed prostate cancer.[7] However, screening remains controversial, in part due to conflicting results from recent large randomised controlled trials. This evidence concerns the gene KLK3 and prostate carcinoma.